GOSSAMER BIO, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
GOSSAMER BIO, INC. (GOSS) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $1.45 million as of 2020-03-31, per its 10-Q filed 2020-05-12.
Discontinued › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2020-05-12
- 2020-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.45M.
- 2019-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.54M.
- 2019-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.63M.
- 2019-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $1.72M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2020-03-31 | $1.45M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $1.54M 10-K · filed 2020-03-24 |
| 2019-09-30 | $1.63M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.72M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |